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INTRODUCTION
Advances in adjuvant therapy for breast cancer have shown
modest gains varying from 1% to 9%. As the magnitude of benefit
decreases, side-effects and quality-adjusted benefits gain impor-
tance. It is important to note that following a relapse, the response
to therapy and improvement in time to progression of disease are
in increments of a few months, and quality-of-life (QOL) issues
are more important in these patients.
In India, the incidence of breast cancer has steadily increased
over the years with 100 000 new cases being diagnosed every
year.1 At a given time, there are as many as 1 million patients with
breast cancer in India. The lifetime risk of developing breast
cancer is 1:30 (incidence rate: 20/100 000) in urban India and
1:65 (incidence rate: 8.6/100 000) in rural India as compared to 1
in 8 in the USA. At the Tata Memorial Hospital (TMH), Mumbai,
a tertiary cancer referral centre in India, about 60% of women
present with early breast cancer, 35% with locally advanced
disease and 5% have metastases at presentation.
Cultural and ethnic influences have a major impact on the
treatment measures and outcomes between western and Indian
women. The European Organization for Research and Treatment
of Cancer (EORTC) module QLQ-C302,3 and the breast cancer-
specific module BR-234 have been validated to assess QOL in
western women with breast cancer. These questionnaires were
designed keeping in mind the lifestyle of western women. The
reliability and validity of the questionnaire has thereafter been
tested and found to be highly consistent across different language
and cultural groups in English-speaking countries, and northern
and southern Europe.2 Whether these modules are equally reliable
in Indian languages and in our cultural milieu has not been
studied. The functional assessment of cancer therapy for breast
cancer (FACT-B) has been reported in some Indian women.5
The standard treatment of primary operable breast cancer
(OBC) includes a combination of surgery, radiotherapy, chemo-
therapy and/or hormone therapy. Large randomized trials6 have
shown that breast conservation treatment (BCT) and modified
radical mastectomy (MRM) for early breast cancer are compa-
rable with respect to the risk of local recurrence and overall
survival. As regards QOL, BCT and mastectomy have been shown
to have different impacts.7–9 While some studies have shown that
173PARMAR et  al. : EORTC QUALITY-OF-LIFE QUESTIONNAIRE IN INDIAN WOMEN WITH BREAST CANCER
compared with mastectomy, BCT resulted in a better overall
QOL,10–13 other studies have shown equivocal7 or even worse14
results.
QOL assessment is an important surrogate end-point in
various clinical trials testing a treatment intervention, in addi-
tion to the actuarial improvement in disease-free survival or
overall survival. While a proportional reduction in the odds of
recurrence or death is observed irrespective of nodal status,15  the
absolute benefit from systemic therapy is clearly more among
those with a higher risk of recurrence.16 Adjuvant radiotherapy is
indicated in all high-risk women with tumours >5 cm in size or
with metastasis in >3 nodes in the axilla.17,18 In such situations
the use of adjuvant chemo-radiation is also indicated, irrespec-
tive of the impact on QOL. The controversies arise in cases that
have a low risk of recurrence and derive a minimal absolute
degree of benefit from adjuvant treatment in the presence of
considerable co-morbid medical conditions or in elderly pa-
tients. The effects on QOL can also be the primary end-point in
certain studies comparing two nearly similar treatment modali-
ties. We translated the QLQ-C30 and BR-23 modules into three
local languages and administered these to ascertain their valid-
ity, and to assess the QOL following surgery and adjuvant
therapy in Indian women with early OBC.
METHODS
Questionnaire
The EORTC module QLQ-C30 is a 30-item questionnaire com-
posed of 5 multi-item functional subscales: physical health, role
function, emotional function, cognitive function and social func-
tioning; 3 multi-item symptom scales measuring fatigue, pain and
emesis; a global health subscale and 6 single items to assess
financial impact and general symptoms.
The BR-23 module evaluates treatment-related symptoms of
breast cancer. It incorporates 3 functional scales (body image,
future perspectives and sexuality) and 4 symptom scales (arm
symptoms, breast symptoms, hair loss and side-effects of systemic
therapy).
Translation methodology
The EORTC office and the clinical research secretariat cell at
TMH coordinated translation of the questionnaire. There were two
rounds of back and forth translation for the purpose of validation.
The translations were done in three Indian languages—Gujarati,
Marathi and Hindi.
Patients
Women with OBC undergoing primary surgery in the Breast Unit
at TMH from October 1998 to September 2001 were included.
Adjuvant systemic therapy and radiotherapy were administered
postoperatively based on the histopathological report of the pa-
tients. None of the women had received neoadjuvant chemo-
therapy or hormone therapy.
The QOL during treatment was objectively assessed with the
EORTC modules QLQ-C30 and BR-23 in English and the trans-
lated versions. A minimal level of education was required for the
patient to be able to read, comprehend and complete the question-
naires on her own.
Management protocol
Women with OBC were treated by a standard protocol in the
Breast Unit, wherein after confirmation of the diagnosis of breast
cancer by fine-needle aspiration cytology (FNAC) or core biopsy,
they underwent BCT or MRM based on the feasibility of conserv-
ing the breast, patients’ choice and compliance with radiotherapy.
On an average, the sutures were removed 12–14 days after surgery
by which time the histopathological report was also available and
adjuvant therapy was planned.
All women with a tumour size >1 cm and/or lymph node
metastasis received adjuvant systemic therapy and were coun-
selled by the breast care nurse. Adjuvant chemotherapy (cyclo-
phosphamide, methotrexate and 5-fluorouracil [CMF] or cyclo-
phosphamide, doxorubicin and 5-fluorouracil [CAF]) was admin-
istered in 6 cycles at 3-weekly intervals. The chemotherapy
schedule lasted 6 months with CMF and 4.5 months with
anthracycline-based chemotherapy. Adjuvant radiotherapy was
administered concurrently with CMF chemotherapy and sequen-
tially after CAF chemotherapy. As per the unit protocol, all
women who underwent BCT received postoperative radiotherapy
and, after mastectomy, the chest wall was irradiated if the tumour
was >5 cm in size or if >3 axillary nodes were positive for
metastasis. Sequential radiotherapy was started approximately 2
weeks after completing CAF chemotherapy and was usually
completed in 6–7 weeks. The adjuvant treatment lasted 8.5+1
months. All women who had endocrine-responsive tumours re-
ceived tamoxifen 20 mg once daily or 10 mg twice daily for 5 years.
After completing adjuvant chemotherapy, the patient was re-
viewed every 6 months.
Data collection
The QLQ-C30 and BR-23 modules were administered at three
time-points. The questionnaire was served for the first time (visit
1) within 2–4 weeks of surgery. The questionnaire was served the
second time (visit 2) when the patient was on adjuvant therapy
(chemotherapy, hormone therapy and/or radiotherapy), 2–8 months
after surgery (average 4.08 months); and the third time (visit 3) it
was served after the completion of adjuvant chemotherapy, 6–18
months after the surgery (average 9.01 months). The breast care
nurse served the questionnaire but the patient herself, unassisted
by the nurse or any other individual, completed the questionnaire.
Thus, only those women who could comprehend the questions
asked were included in the study. Only those women who com-
pleted the QOL questionnaire on all the 3 visits were included in
the final analysis.
Statistical analysis
Scoring of the QLQ-C30 and BR-23 was done according to the
scoring procedures described in the EORTC scoring manuals. A
range of analyses was conducted to establish scale reliability and
to evaluate the validity of the questionnaire. Reliability or internal
consistency of the multi-item questionnaire scales for the entire
sample was assessed by Cronbach alpha coefficient. A magnitude
of >0.70 was sought. Multitrait scaling analysis was used to
examine the extent to which the items of the questionnaire could
be combined into a hypothesized multi-item scale by item–scale
correlation. If the item–scale correlation coefficient was >0.40,
item convergent validity was considered acceptable.
Statistical methodology
The type of surgery performed (MRM or BCT) and whether
adjuvant chemotherapy, radiotherapy or hormone therapy was
given or not, were used to divide the patients into subgroups as we
expected health-related QOL to differ among the groups.
Non-parametric tests were used because of non-normal distri-
bution of scores. The Mann–Whitney U test was used to compare
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scores between the two groups at each visit and the Friedman test
to test for changes over time.
The global QOL score (q29, q30 in QLQ-C30) has a normal
distribution. Analysis of variance for repeated measures was used
for comparing global QOL scores between types of surgery and
adjuvant therapy.
RESULTS
Two hundred and ninety-nine women were included in the study.
Of these, 274 (91.6%) completed the questionnaire on visit 2 and
239 (80%) on visit 3. One hundred and ninety-three women
(64.5%) completed all the three visits within the specified time
periods and were included in the final analysis as valid visits; 60
forms were completed in English and 133 in the translated local
language version. The mean age of the women was 44.2 years
(range 24–72 years); 67% of women were premenopausal and
33% postmenopausal (Table I).
The tumours were reported as infiltrating duct carcinoma in
89.7% of cases, ranging from 0.1 to 7.0 cm with a mean tumour
size of 3.25 cm. The tumours were positive for oestrogen receptors
in 26% of cases and progesterone receptors in 41%. BCT was done
in 60.1% of women. Based on the treatment protocol and eligibil-
ity criteria, 90% of women received adjuvant chemotherapy, 51%
hormone therapy and 75% radiotherapy.
Cronbach alpha (Table II) and individual item–scale correla-
tion tested the validity and reliability of the QLQ-C30 and BR-23
questionnaires. The reliability of the questionnaire results was
confirmed, as a value of nearly 0.70 or greater was obtained for all
domains except cognitive function.
The translated versions were validated by Cronbach alpha and
the scores between the English version and translated versions
were compared at visit 1 (Table III). There was no statistically
significant difference.
The effect of surgery on QOL was assessed linearly with time,
i.e. between visit 1 and visit 3 using Friedman test, and also
between types of surgery performed (BCT v. mastectomy) using
the Mann–Whitney U test. The global QOL scale, functional
scales and symptom scales showed no significant change from
visits 1 to 3 between BCT and mastectomy. Women who under-
went BCT maintained a better body image through visit 1 (p<0.001)
and visit 2 (p=0.055) compared with women who underwent
mastectomy. The differences disappeared by visit 3 (average 9
months after surgery). Women who had BCT had significantly
more local symptoms than after mastectomy in visits 2 and 3
(p<0.01). This corresponded with the period of adjuvant radio-
therapy (Table IV).
Chemotherapy significantly affected the global QOL with poor
scores during treatment (p=0.016). The results also showed lower
functional scales especially with respect to sexual function (p=0.02)
after chemotherapy. Women receiving chemotherapy experienced
severe nausea and vomiting (p<0.001), were upset over hair loss
(p<0.001), and had more arm symptoms (p<0.01) and systemic
effects (p<0.001; Table V).
Adjuvant radiotherapy resulted in deterioration in social func-
tions (p=0.02) during treatment, with significantly more breast
symptoms (p<0.001) as compared with women not receiving
adjuvant radiotherapy (Table VI). Hormone therapy had no sig-
nificant effect on the QOL as assessed by both questionnaires.
DISCUSSION
The EORTC developed the 30-item QOL questionnaire (QLQ-
C30) as a self-supporting, cancer-specific measure of health-
TABLE I. Demographic profile of patients included in QOL study
(n=193)
Parameter n (%)
Occupation
Housewife 135 (69.9)
Service 51 (26.4)
Professional/Others 7 (3.7)
Education
Primary 101 (52.3)
Secondary 31 (16.1)
Graduation  42 (21.8)
Postgraduation 19 (9.8)
Marital status
Unmarried 8 (4.1)
Married  174 (90.2)
Divorcee/Widow 11 (5.7)
Menopausal status
Premenopausal  129 (66.9)
Postmenopausal 64 (33.1)
Type of surgery
Modified radical mastectomy 77 (39.9)
Breast conservation treatment 116 (60.1)
Histology
Infiltrating duct carcinoma  173 (89.7)
Others 20 (10.3)
TABLE II. Reliability and validity of the EORTC questionnaire by
Cronbach alpha (n=193)
Internal consistency (Cronbach alpha) of the QLQ-C30 scales
Visit Functioning Fatigue Pain Nausea/ QOL
P R E C S vomiting
1 0.64 0.78 0.85 0.49 0.76 0.76 0.66 0.57 0.86
2 0.75 0.76 0.86 0.46 0.81 0.76 0.70 0.66 0.91
3 0.75 0.81 0.90 0.62 0.76 0.84 0.76 0.74 0.96
Internal consistency (Cronbach alpha) of the QLQ–BR23 scales
Visit Body Sexual Symptoms Side-effects of
image functioning Arm Breast systemic therapy
1 0.81 0.81 0.73 0.66 0.61
2 0.84 0.83 0.70 0.77 0.80
3 0.86 0.91 0.75 0.59 0.59
P Physical R Role E Emotional C Cognitive S Social
TABLE III. Comparison of Cronbach alpha score between the
English version and translated Indian language versions of
EORTC QLQ-C30 and BR-23
Item scales English Translated versions
Functioning
Physical  0.617  0.656
Role 0.827 0.738
Emotional 0.831 0.831
Cognitive 0.233 0.437
Social 0.784 0.787
Quality-of-life 0.803 0.832
Systemic side-effects 0.641 0.707
Body image 0.782 0.814
Sexual functioning 0.883 0.744
Arm symptoms 0.654 0.735
Breast symptoms 0.716 0.647
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related QOL. The QLQ-C30 was intended to be applicable across
a wide range of cancer diagnoses and treatments. Its main purpose
was to obtain information about the impact of disease and treat-
ment on the daily living of patients with cancer. One of the largest
validation studies for QLQ-C30 was reported by McLachlan et
al.3 in 150 Canadian women with metastatic breast cancer. The
findings supported the use of QLQ-C30 subscales for assessing
global health, role function, social function and emotional func-
tion. The module BR-23 was added later4 as a breast cancer-
specific questionnaire to supplement the core instrument and thus
be highly relevant for assessing the QOL of patients with breast
cancer participating in clinical trials.
The reliability and validity of the EORTC instrument has been
tested not only in western women but also in women from the east
(Korea) and those from a different religious following (Turkish).
In the Korean study, in a known-group comparison, there were
marked group differences between patients differing in the stage
of disease. The performance on the Korean version of the EORTC
QLQ-BR23 questionnaire was in the expected direction for almost
all functioning and symptom scores, and compared well between
normal individuals and patients with breast cancer.19 The Turkish
study was carried out in 202 patients with lung cancer and tested
TABLE IV. Comparative QOL assessments between visits 1 and 3
by the Friedman test, and within each visit between breast
conservation treatment (BCT) and modified radical
mastectomy (MRM) by Mann–Whitney U test
Item scale Therapy Visit 1 Visit 2 Visit 3 p value*
Functioning
Physical MRM 77.14 (16.2) 76.10 (16.9) 76.71 (18.4) 0.95
BCT 80.86 (12.5) 74.19 (17.8) 78.41 (16.5) 0.002
p value† 0.14 0.41 0.63
Role MRM 75.76 (27.1) 76.84 (26.6) 80.30 (24.4) 0.211
BCT 74.85 (27.4) 76.87 (23.4) 84.34 (22.9) 0.001
p value† 0.79 0.69 0.18
Emotional MRM 69.08 (23.6) 67.98 (27.2) 71.05 (27.5) 0.42
BCT 69.60 (24.2) 71.09 (24.4) 70.51 (24.7) 0.001
p value† 0.63 0.57 0.76
Social MRM 74.78 (28.1) 72.37 (28.7) 74.56 (28.2) 0.58
BCT 77.39 (28.9) 75.79 (28.5) 81.73 (23.4) 0.04
p value† 0.52 0.38 0.12
Cognitive MRM 85.75 (21.6) 78.20 (23.3) 82.24 (20.9) 0.004
BCT 88.55 (17.2) 84.34 (19.7) 81.01 (21.9) 0.001
p value† 0.46 0.08 0.75
Body MRM 73.05 (23.9) 72.94 (26.5) 71.43 (31.1) 0.83
image BCT 88.48 (17.3) 80.58 (22.7) 82.80 (21.1) <0.001
p value† <0.001 0.055 0.47
Symptoms
Arm MRM 37.33 (22.9) 26.22 (22.8) 30.52 (25.1) <0.001
BCT 32.75 (21.1) 29.19 (21.5) 27.34 (20.7) 0.013
p value† 0.29 0.17 0.64
Breast MRM 18.46 (16.3) 15.30 (16.6) 16.51 (18.5) 0.57
BCT 19.73 (17.7) 28.19 (21.9) 22.92 (18.6) 0.005
p value† 0.67 <0.0001 0.003
Systemic MRM 16.08 (13.6) 32.89 (19.7) 28.14 (20.9) <0.001
therapy BCT 13.83 (11.6) 34.91 (20.3) 27.77 (19.5) <0.001
side-effects p value† 0.47 0.59 0.95
Sexual MRM 81.34 (23.3) 74.88 (27.1) 72.88 (26.7)
functioning BCT 79.57 (23.1) 75.16 (23.8) 73.04 (25.4) 0.036
p value† 0.69 0.79 0.89
* Friedman test † Mann–Whitney U test
Figures in parentheses indicate + standard deviation
TABLE V. QOL assessment between visits 1 and 3 by the
Friedman test, and within each visit between those receiving
and not receiving chemotherapy by Mann–Whitney U test
Item scale Therapy Visit 1 Visit 2 Visit 3 p value*
Functioning
Physical Yes 79.84 (13.5) 74.64 (17.7) 77.37 (17.4) 0.01
No 75.09 (19.4) 77.89 (14.8) 81.05 (16.5) 0.14
p value† 0.37 0.55 0.34
Role Yes 74.62 (27.1) 76.15 (24.1) 81.99 (23.6) 0.001
No 80.70 (28.5) 83.33 (29.4) 89.47 (22.4) 0.10
p value† 0.21 0.06 0.72
Cognitive Yes 87.19 (19.1) 81.69 (21.4) 80.92 (21.6) <0.001
No 89.81 (18.2) 84.26 (20.9) 87.04 (20.3) 0.72
p value† 0.52 0.56 0.25
Body Yes 81.98 (21.5) 77.22 (24.2) 77.78 (25.6) 0.012
image No 85.09 (22.2) 80.26 (27.7) 82.46 (30.2) 0.38
p value† 0.33 0.27 0.72
Symptoms
Arm Yes 34.63 (21.9) 28.75 (21.6) 29.53 (22.0) <0.001
No 33.95 (22.1) 20.99 (26.1) 19.75 (26.0) 0.003
p value† 0.72 0.03 0.009
Systemic Yes 15.21 (12.7) 36.33 (19.3) 29.6 (19.3) <0.001
therapy No 10.27 (8.3) 13.78 (14.6) 12.32 (20.6) 0.63
side-effects p value† 0.12 <0.001 <0.001
Sexual Yes 79.76 (23.7) 75.11 (25.5) 72.84 (26.3) 0.006
functioning No 85.56 (15.3) 74.44 (20.1) 74.44 (20.8) 0.09
p value† 0.59 0.99 0.66
* Friedman test † Mann–Whitney U test
Figures in parentheses indicate + standard deviation
TABLE VI. Adjuvant radiotherapy and quality-of-life
Item scale Therapy Visit 1 Visit 2 Visit 3 p value*
Functioning
Physical Yes 80.42 (13.6) 73.84 (18.2) 77.52 (16.9) 0.001
No 76.33 (15.5) 78.23 (14.6) 78.37 (18.4) 0.15
p value† 0.66 0.17 0.55
Role Yes 75.58 (26.4) 76.39 (28.0) 83.45 (28.5) 0.001
No 74.15 (29.7) 78.23 (26.8) 80.61 (23.6) 0.343
p value† 0.91 0.396 0.28
Social Yes 76.29 (28.4) 73.94 (28.7) 80.16 (24.2) 0.02
No 76.53 (29.6) 75.85 (28.5) 75.17 (29.1) 0.97
p value† 0.81 0.60 0.37
Cognitive Yes 87.09 (19.9) 82.28 (21.2) 81.69 (22.1) 0.001
No 88.44 (16.0) 80.95 (21.8) 80.95 (19.3) 0.06
p value† 0.93 0.82 0.63
Body Yes 84.73 (20.9) 77.97 (23.8) 78.65 (25.6) <0.001
image No 75.17 (22.1) 76.19 (26.8) 77.04 (27.8) 0.29
p value† 0.003 0.93 0.84
Symptoms
Arm Yes 34.20 (22.1) 29.75 (22.2) 29.83 (22.8) 0.009
No 35.65 (21.6) 22.92 (20.9) 25.00 (21.6) <0.001
p value† 0.77 0.27 0.214
Breast Yes 19.87 (17.6) 26.94 (21.3) 23.39 (19.7) 0.014
No 17.27 (15.8) 11.59 (11.0) 11.29 (11.9) 0.29
p value† 0.50 <0.001 <0.001
Systemic Yes 15.00 (12.9) 35.68 (20.7) 28.85 (20.4) <0.001
therapy No 13.89 (10.9) 29.62 (17.4) 28.17 (18.6) <0.001
side-effects p value† 0.72 0.14 0.39
Sexual Yes 78.84 (23.1) 75.26 (28.1) 73.94 (24.1) 0.07
functioning No 84.49 (22.8) 74.42 (25.3) 70.16 (30.6) 0.002
p value† 0.17 0.98 0.89
* Friedman test †Mann–Whitney U test
Figures in parentheses indicate + standard deviation
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the validity of the Turkish version of the EORTC QLQ-C30 v. 2.0.
All subscales met the minimal standards of reliability. Global
QOL was substantially correlated with most of the scales except
cognitive functioning.20
Our study on Indian women with breast cancer confirmed the
reliability and validity of the EORTC QLQ-C30 in assessing the
overall QOL of Indian women with breast cancer. The BR-23 was
also validated in the current study, as the breast symptoms, body
image and systemic therapy side-effects scales were clearly re-
sponsive to treatment-induced changes.
The validity and reliability of the translated versions of the
QOL questionnaire were tested by comparison between the En-
glish version group and the local language version groups. The
similarity of Cronbach alpha values obtained validates the local
language version for use among Indian women. The validation
was further consolidated by the observations made with respect to
QOL assessment during treatment of breast cancer.
Our study showed no difference in any aspect of overall QOL
between BCT and MRM except body image, which was signifi-
cantly better after BCT and breast symptoms which worsened
during and after radiotherapy in the BCT group. The differences,
however, disappeared by visit 3 (average 9 months after surgery)
indicating a late coping capability and adjustment with self-image
in women after MRM. A study by Kiebert et al.8 supports the
findings of our study. They reviewed 18 studies investigating the
impact of BCT v. MRM on QOL with respect to treatment
modality, stage of disease, methodological issues and end-results
(psychological discomfort, change in pattern of life, and fears and
concerns). Only a better body image and sexual functioning
favoured the use of BCT.
The impact of BCT and MRM on QOL has shown contradic-
tory results in different studies. A comparative study in Munich12
in 152 pair-matched patients evaluated the QOL in women ini-
tially treated for stages I–III breast cancer without evidence of
distant metastasis. In this study, the QOL questionnaire was
answered after a median interval of 46 months following primary
treatment. No difference was observed between the two groups in
terms of all QOL items as measured by the QLQ-C30. However,
certain additional questions revealed that women in the mastec-
tomy group were less satisfied with the cosmetic result of their
primary operation (p<0.0001), were more likely to feel the basic
changes in their appearance (p<0.0001) and were more likely to be
emotionally stressed by these facts (p<0.0001). In contrast, Cohen
et al.14 found that women who had BCT experienced significantly
greater levels of psychological distress and marginally worse
QOL 40 months after surgery than women who underwent MRM.
Both these studies have looked at the late effects of BCT v. MRM
on the QOL. The early effect on QOL has been assessed mainly in
relation to radiation therapy after BCT. In a randomized trial
setting, the Ontario Clinical Oncology Group21 studied serial QOL
in two groups of women with lymph node-negative breast cancer
who underwent BCT; radiotherapy following BCT and those who
did not. Breast irradiation resulted in increased breast symptoms
compared with controls during and after the treatment, which
disappeared by 2 years post treatment.
Adjuvant systemic therapy for early breast cancer is effective
but is known to be associated with significant side-effects. In our
study too, chemotherapy resulted in significant symptoms such as
nausea and vomiting (p<0.001). Also, patients were most upset
over hair loss and had more arm symptoms after chemotherapy
(p<0.001).
Adjuvant radiotherapy resulted in mainly local symptoms in
the arm (p=0.009) and breast (p<0.001), which were also associ-
ated with deterioration in social function (p<0.021). The impact
on other function scales was not significant. There were no
systemic effects of radiotherapy.
Adjuvant hormone therapy had no effect on QOL during
treatment. Vaginal dryness was experienced by most women due
to increased vaginal epithelial proliferation but did not signifi-
cantly affect their sexual life.
Conclusion
The EORTC questionnaires QLQ-C30 and BR-23 are applicable
to Indian women in spite of major language and cultural differ-
ences from western society. The QOL scores of the translated
versions were similar to the original English version and, there-
fore, can be used to assess the QOL of  Indian women. The
statistical analysis of a QOL questionnaire is itself a process in
evolution. It has many shortcomings, multiple comparisons, ob-
jective conversion of a subjective feeling, etc. These need to be
considered before any conclusions are drawn from a QOL analy-
sis.
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